Gossamer Bio Q3 net loss $30.8M; cash $327M, runway into H1 2027

Gossamer Bio, Inc.

2024-Q3 EPS reported -$0.10 revenue$105,322,000

Net loss of $30.8M ($0.14/share) vs $40.0M ($0.21/share) in Q3 2023; revenue from Chiesi collaboration was $9.5M.
Cash, cash equivalents & marketable securities $327M as of Sept 30, 2024; expected to fund operations into H1 2027.
Phase 3 PROSERA trial in PAH enrollment ongoing; topline results expected Q4 2025.
Expect to commence global registrational Phase 3 trial for PH-ILD in mid-2025.
R&D expenses $34.9M (up from $31.2M); G&A $8.5M (down from $9.3M) YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.